NCT01919749已完成不适用
A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Determine the impact of targeted therapy for breast cancer based upon proteomic and genomic profiling using RPMA, IHC analysis, RNA-Seq, and Exome sequencing on PFS and GMI.
研究概览
简要总结
This study will use proteomic and genomic profiling to analyze tumor tissue to see if treatment selected by this analysis will benefit patients.
详细描述
To examine the impact of targeted therapy for breast cancer based upon proteomic and genomic profiling using RPMA, IHC analysis, RNA-Seq, and Exome sequencing on PFS and GMI.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and provide written informed consent and HIPAA Authorization prior to initiation of any study-specific procedures
- •Have a life expectancy > 3 months
- •Have a diagnosis of metastatic breast cancer with measurable disease (RECIST 1.1)
- •Have progressed on ≥ 1 prior chemotherapeutic and/or hormonal regimen for advanced disease.
- •Have documentation of progression (by RECIST 1.1) on the treatment regimen immediately prior to entering this study
- •Be ≥ 18 years of age
- •Have a ECOG score of 0-1
- •Be a good medical candidate for and willing to undergo a biopsy or surgical procedures to obtain tissue, which may or may not be part of the patient's routine care for their malignancy. The requirements for the amount of tissue required for analysis are detailed in Section 6.2.
- •Have been off their prior regimen for ≥ 3 weeks or 5 x half-life of drug, whichever is shorter and have recovered from the side effects (≤ grade 1) of that regimen
- •Have adequate organ and bone marrow function
- •Female patients of childbearing potential must have a negative pregnancy test and agree to use at least one form of contraception during the study and for at least one month after treatment discontinuation. For the purposes of this study, child-bearing potential is defined as: all female patients that were not in post-menopause for at least one year or are surgically sterile
- •Male patients must use a form of barrier contraception approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation.
排除标准
- •Have a tumor biopsy intended for use in the current study that was performed more than 2 months prior to analysis
- •Have metastatic lesion that is not accessible to biopsy
- •Had > 6 months treatment under the last line of therapy
- •Have interventional cancer therapy conducted after the biopsy was collected prior to analysis
- •Have symptomatic CNS metastasis. Patients with a history of CNS metastases who have been treated with whole brain irradiation must be stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on a stable dose of steroids for ≥ 2 weeks prior to enrollment
- •Have any previous history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry
- •Have uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
- •Have known HIV, HBV, HCV infection
- •Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.
研究组 & 干预措施
treatment
Other
recommended treatment
干预措施: treated recommended (Other)
结局指标
主要结局
Determine the impact of targeted therapy for breast cancer based upon proteomic and genomic profiling using RPMA, IHC analysis, RNA-Seq, and Exome sequencing on PFS and GMI.
时间窗: 24 months
Determine the impact of targeted therapy for breast cancer based upon proteomic and genomic profiling using RPMA, IHC analysis, RNA-Seq, and Exome sequencing on PFS and GMI.
次要结局
- Record the frequency with which proteomic, IHC, and genomic profiling analysis of a patient's tumor by RPMA, IHC analysis, RNA-Seq, and Exome sequencing yields a target against which there is an FDA-approved agent or therapeutic regimen.(24 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive GlioblastomaAdult GlioblastomaNCT02060890University of California, San Francisco20
终止
不适用
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast CancerBreast CancerNCT00235235Hoosier Cancer Research Network80
已完成
不适用
Functional Precision Oncology for Metastatic Breast CancerHER2-negative Breast CancerNCT04450706University of Utah15
招募中
不适用
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT02215928Stanford University100
终止
不适用
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast CancerBreast CancerNCT00537173Hoosier Cancer Research Network11